OTC statins
This article was originally published in The Tan Sheet
Executive Summary
Nonprescription sale of 10 mg simvastatin (Merck's Zocor) in the UK may "be leading to an era of less aggressive statin therapy," according to a statistical analysis presented at the Annual Scientific Sessions of the American College of Cardiology in Atlanta, Ga. March 13. OTC sale, which began in 2004, "has had an immediate and substantial impact on statin prescriptions," Kristian Filion, et al., Royal Victoria Hospital, Montreal, Canada, state. Researchers recorded statin prescriptions in the General Practice Research Database (GPRD) from the beginning of 2001 until the first quarter of 2005. Filion et al. observe that after years of increasing use, the number of statin prescriptions in the UK fell for the first time in the first quarter of 2005. "If we extrapolate from the GPRD population to the UK population of approximately 60 mil., we predict approximately 350,000 fewer statin prescriptions per quarter in the UK due to this policy change," they state. The decline in Rx statins also was not limited to 10 mg statins, but included 20 mg doses as well...
You may also be interested in...
Switch Environment Makes U.K. A Sound Warm-up For Centralized Switch
The U.K.'s bullish Rx-to-OTC switch environment can make it an attractive place to try a switch before pursuing the EU-wide centralized procedure, which contains more potential pitfalls, experts say
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.